Barata, P. C., Tincknell, G., Gill, D. M., Fu, S. Y. F., Singh, A., Sartor, A. O., Cade, D., Agarwal, N. (2026). Safety and dosimetry of 177 Lu-rosopatamab tetraxetanplus SoC in patients with metastatic castration-resistant prostate cancer: Preliminary results from part 1 of phase 3 ProstACT Global study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba5009